Fairvalue-Calculator Fairvalue-Calculator
EN DE

Carlsmed, Inc (CARL) Fair Value & Analysis

Healthcare · US · Market cap $274M

Price$10.69
Fair Value$16.37
Upside+53.1%
Quality87/100
Evidence: Low Range $12.27 – $20.46

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Carlsmed, Inc (CARL) currently trades at $10.69, while our model-based Fair Value estimate is $16.37 — implying the stock looks roughly 53.1% undervalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.

Open the full interactive analysis →

Similar stocks

Veeva Systems Inc (VEEV) -37% Pro Medicus Limited (PME) -79% BrightSpring Health Services, Inc (BTSG) -61% Tempus AI, Inc (TEM) -74% HealthEquity, Inc (HQY) -39% M3, Inc (MTHRY) +48%

Frequently asked questions

Is Carlsmed, Inc (CARL) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $16.37 versus a price of $10.69 — about +53% (undervalued). Model-based estimate, not financial advice.
What is the fair value of CARL?
Our 21-model fair value for Carlsmed, Inc is $16.37 (as of Jun 24, 2026), built from audited fundamentals. The current price is $10.69.
What is the quality score of CARL?
Carlsmed, Inc has a Quality Score of 87/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.